Nebivolol-Actavis

Quick links

Choose a section

Quick links to important sections

Advertisements

Nebivolol-Actavis

Advertisements
Advertisements

Overview of Nebivolol-Actavis

Property Description
Active ingredient Nebivolol (racemic mixture)
Form Film-coated tablets
Pharmacological class Beta-blocker (Selective beta1 adrenergic receptor antagonist)
Origin Synthetic
Classification Third-generation beta-blocker

Classification and Identity as a Beta-Blocker

Nebivolol-Actavis is a specific pharmaceutical preparation supplied by Actavis that utilizes the synthetic, prescription-only compound Nebivolol as its active substance. This ingredient belongs to the pharmacological class known as beta-blockers (beta-adrenergic receptor antagonists), a group of medicines clinically recognized for their role in modulating cardiovascular activity. Nebivolol is distinctively categorized as a third-generation beta-blocker, a classification supported by pharmacological studies demonstrating its unique ability to not only block receptors but also to promote dilation of the blood vessels. This dual functionality positions it as an advanced agent for managing circulatory requirements.

Active Ingredient, Composition, and Dosage Form

The product is formulated as a film-coated tablet designed for oral administration. Its composition features the single active substance, Nebivolol, which exists as a racemic mixture of two functional molecules: D-Nebivolol and L-Nebivolol. This compositional detail is critical, as the L-isomer significantly contributes to the compound's unique ability to dilate blood vessels, while the D-isomer delivers the primary beta-blocking activity. The tablet form ensures the precise and simultaneous delivery of both active mechanisms.

The General Purpose of Nebivolol’s Dual Action

The overall general purpose of Nebivolol’s dual action is to promote more efficient circulatory function for patients, typically in scenarios requiring consistent management of vascular pressure. By combining selective heart rate and force control with vascular relaxation and expansion, the drug helps balance the forces within the cardiovascular system. The compound’s mechanism, mediated by the stimulation of Nitric Oxide (NO) release, is recognized for providing a comprehensive approach to managing both the heart’s workload and the tension in the peripheral blood vessels.

Regulatory References

  1. NEBIVOLOL - DailyMed
Advertisements

What side effects are possible with Nebivolol-Actavis?

Possible Side Effects and Safety Information

The safety profile of Nebivolol-Actavis is structured by official frequency classifications and specific warnings from regulatory authorities.

Adverse Reactions by Frequency

Classification System-Organ Classes Involved (Examples) Key Adverse Reactions
Common (1% to 10%) Nervous, General, Gastrointestinal Headache, dizziness, fatigue, peripheral edema, tiredness, constipation, nausea, diarrhea. Bradycardia is common in heart failure treatment.
Uncommon (0.1% to 1%) Cardiac, Vascular, Psychiatric, Skin Bradycardia (hypertension), worsening heart failure, hypotension, nightmares, depression, impotence, bronchospasm, pruritus, erythematous rash.
Very Rare (<0.01%) Nervous, Skin Syncope, psoriasis aggravated.
Not Known Immune System Angioneurotic oedema, hypersensitivity, urticaria.

Regulatory Warnings and Limitations

  • Abrupt Discontinuation Risk: Stopping therapy suddenly, particularly in patients with coronary artery disease, has been associated with severe exacerbation of angina, myocardial infarction, and ventricular arrhythmias. Therapy should be gradually tapered over 1 to 2 weeks when possible.
  • Contraindications: Nebivolol is strictly contraindicated in cases of severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (without a pacemaker), severe hepatic impairment (Child-Pugh Class B or C), and hypersensitivity to the product.
  • Specific Safety Considerations: Use requires caution in patients with bronchospastic diseases, peripheral vascular disease, and diabetes, as the drug may mask certain symptoms of hypoglycemia, such as tachycardia. It is also contraindicated during the second and third trimesters of pregnancy due to potential fetal toxicity. Dosage adjustment is required for patients with severe renal impairment.
Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

A suspected overdose of Nebivolol-Actavis requires immediate medical attention, as officially mandated by regulatory authorities. Contacting emergency services is necessary to receive guidance and initiate appropriate management.

Documented Clinical Manifestations

Official labeling states that overdose may present with signs of profound cardiovascular depression. The core manifestations include bradycardia (excessively slow heart rate), severe hypotension (low blood pressure), and acute cardiac failure. Other documented clinical signs are bronchospasm (severe breathlessness), dizziness, fatigue, and vomiting.

Severe and Life-Threatening Outcomes

The profile of severe outcomes includes conditions such as second- or third-degree heart block, depressed level of consciousness, and respiratory failure. Additionally, severe metabolic disturbances, specifically hypoglycemia and hypokalemia, are officially recognized possibilities in overdose scenarios.

Official Management and Supportive Care

Overdose management, as described in regulatory documents, involves general supportive and specific symptomatic treatment. Since official information states that hemodialysis is not expected to enhance drug clearance, treatment focuses on interventions such as the administration of IV atropine and glucagon for refractory bradycardia and hypotension. Specific agents like vasopressors and IV fluids are used to maintain circulatory stability, and pacemaker placement may be required in severe cases.

Advertisements

Therapeutic Uses of Nebivolol-Actavis

Nebivolol-Actavis: Main Therapeutic Uses

Nebivolol-Actavis is a beta-blocker commonly used to help with conditions presenting with acute episodes in the cardiovascular system.

The product is applied in addressing conditions where symptoms may intensify temporarily, such as essential hypertension (high blood pressure) and stable mild and moderate chronic heart failure (in addition to standard therapies in elderly patients aged 70 years or over).


The medication is relevant for easing symptoms related to heightened physiological activity. It provides support that helps ease the overall symptom burden associated with systemic imbalance. The drug is applied in clinical settings that involve acute or unstable symptom patterns.

“The medication supports general well-being during symptomatic phases.”

The medication is used in situations involving recurrent or episodic manifestations, such as essential hypertension and chronic heart failure. This approach helps patients cope more steadily with symptom fluctuations and assists with maintaining functional stability, and may be part of symptomatic management in contexts involving heightened systemic burden.

Quick Fact: Helps with symptoms related to heightened physiological activity

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Nebivolol-Actavis?

The eligibility for Nebivolol-Actavis is defined by official regulatory labeling, focusing on a patient's cardiovascular health, organ function, and age.


Eligibility Status Based on Regulatory Documents

Category Official Regulatory Classification
Allowed Populations Adults with Essential Hypertension; Adults aged 70 years and over with Stable Mild and Moderate Chronic Heart Failure.
Not Recommended Children and adolescents under 18 years (safety/efficacy not established); Breastfeeding patients.
Conditional Use Patients with Severe Renal Impairment or Moderate Hepatic Impairment require an adjusted initial dose.

Contraindicated Populations (Must Not Use)

The medicine is absolutely contraindicated in patients with a history of:

  • Severe Bradycardia or Heart Block greater than first degree.
  • Cardiogenic Shock or Decompensated Cardiac Failure.
  • Sick Sinus Syndrome (unless a pacemaker is present).
  • Severe Hepatic Impairment (Child-Pugh Class C).
  • Untreated Phaeochromocytoma or Metabolic Acidosis.
  • Hypersensitivity to Nebivolol or any component.

Additional Restrictions

Pregnancy: Use during the second and third trimesters is associated with a risk of fetal toxicity, and discontinuation is advised promptly upon detection of pregnancy. Use in patients with bronchospastic diseases (e.g., asthma) requires caution and is generally not recommended.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nebivolol’s official regulatory profile details documented interaction patterns with other medicinal products and substances, categorized by their mechanistic impact or associated administration restrictions.


Pharmacodynamic and Contraindicated Interactions

Interaction Type Interacting Agents (Examples) Official Regulatory Statement
Contraindicated Other beta-blockers Co-administration is prohibited due to the risk of excessive beta-blocking effects.
Additive Effects Non-dihydropyridine Ca^2+ Channel Blockers (Verapamil, Diltiazem), Digitalis Glycosides Increase the risk of excessive reductions in heart rate or cardiac contractility.
Antagonism Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May result in the loss of Nebivolol’s antihypertensive effect.

Pharmacokinetic and Timing Restrictions

Metabolic Pathway Interference

Nebivolol is metabolized by the enzyme CYP2D6. Co-administration with agents classified as strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) results in a significant pharmacokinetic interaction, causing increased systemic exposure to the active component of Nebivolol, as documented in the prescribing information.

Administration Timing

Specific sequencing and separation rules apply to certain combinations:

  • Antacids (Aluminum Hydroxide): Administration must be separated from Nebivolol by at least two hours to prevent interference with drug absorption.
  • Clonidine: If discontinuing co-therapy, Nebivolol must be stopped for several days before the gradual tapering of Clonidine.

Population Note: Regulatory labeling identifies CYP2D6 Poor Metabolizers as a population group that naturally attains substantially elevated systemic Nebivolol exposure.

Advertisements

Mechanism of Action

How Nebivolol-Actavis Works: The Dual Mechanism

Nebivolol-Actavis operates through a dual and complementary mechanism delivered by its two isomers, D-Nebivolol and L-Nebivolol, which affect both the heart's functional output and the resistance of the peripheral blood vessels.

Selective beta1 Receptor Blockade

The D-Nebivolol component acts as a highly selective antagonist of the beta1-adrenergic receptor predominantly found in the heart. By blocking this receptor, the drug prevents the stimulating effects of sympathetic hormones (catecholamines). This action initiates a cascade that results in negative chronotropy (slower rate) and negative inotropy (reduced force), lowering the heart’s overall pumping output.

Nitric Oxide-Mediated Vasodilation

The L-Nebivolol component provides a second, distinct mechanism by activating the beta3-adrenergic receptor on the vascular endothelium. This interaction enhances the enzyme Endothelial Nitric Oxide Synthase (eNOS), leading to increased production and release of Nitric Oxide (NO). NO acts as a signaling molecule, which facilitates the relaxation of vascular smooth muscle cells, leading to a decrease in Systemic Vascular Resistance (SVR). The simultaneous actions of both isomers affect the regulation of both cardiac output and peripheral resistance.

Advertisements

Dosage and Administration Information

Nebivolol-Actavis is administered solely through the oral route, typically as a once-daily dose. The tablet may be taken either with or without food, but it is generally required that the intake occurs at the same time each day to ensure a consistent schedule.

Dosing regimens differ based on the regulatory scope of the application. For essential hypertension, the standard protocol begins with a 5 mg dose taken once daily, with dose adjustments permitted at intervals of 2 weeks to achieve the documented effect. The maximum labeled dose for this use is 40 mg once daily.

In the context of stable chronic heart failure in elderly patients (aged 70 years and over), the European protocol requires a detailed titration sequence. Treatment starts at 1.25 mg once daily—a dose often achieved by dividing a scored tablet—and is doubled at 1-to-2 weekly intervals up to a maximum dose of 10 mg. The initiation of this specific therapy, including the first dose increase, requires close medical supervision for at least two hours.

Dose adjustments are also specified for patients with severe renal impairment or moderate hepatic impairment, who should begin therapy with a reduced starting dose of 2.5 mg once daily. Use of this medicine is not recommended for pediatric patients under 18 years of age. If a dose is missed, patients should skip the forgotten dose and resume the normal schedule if the time for the next dose is near, rather than taking a double quantity. Discontinuation of this medicine must always involve gradual dose reduction over a period of approximately one to two weeks.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nebivolol-Actavis


Evidence for Use in High Blood Pressure (Essential Hypertension)

The evidence base for Nebivolol-Actavis was studied for use in conditions characterized by high blood pressure, built primarily through Randomized Controlled Trials (RCTs). These studies monitored the change in seated systolic and diastolic blood pressure as the main measure over short- to intermediate-term follow-up. Findings describe patterns observed in the studies regarding measured blood pressure levels. What remains uncertain is the availability of large, long-term trials tracking major cardiovascular outcomes (such as stroke or myocardial infarction) in direct comparison to other widely used drug classes.


Evidence for Use in Chronic Heart Failure

Research examined the use of Nebivolol-Actavis as an add-on to standard therapies for stable mild and moderate chronic heart failure, centered on one large, placebo-controlled, morbidity and mortality outcomes trial. This trial was applied in research contexts exploring outcomes in a specific population of elderly patients aged 70 years or over. Studies monitored a key composite endpoint that combined the time to first occurrence of all-cause mortality or hospitalization due to cardiovascular causes. The results apply only to these populations studied.


Study Gaps and Evidence Limitations

Research highlights what is known—and what is still uncertain—about this compound. The available research includes short-term and intermediate-term follow-up. Long-term effects are not fully established and there is limited information for periods extending many years beyond the clinical trials. A key limitation is that the heart failure evidence is largely concentrated in the elderly population (≥70 years). Furthermore, subgroup analyses described that the compound was not associated with a change in the key composite outcome in patients with co-existing Atrial Fibrillation (AF), indicating inconsistent findings in this specific subgroup.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Nebivolol-Actavis (FAQ)

Q: How quickly should I expect Nebivolol-Actavis to start lowering my blood pressure?

A: According to official product information, the initial effect of Nebivolol-Actavis on blood pressure typically begins after 1 to 2 weeks of starting treatment. The full, optimal reduction in blood pressure may sometimes take up to 4 weeks to be achieved.

Q: Is it okay to stop taking Nebivolol-Actavis suddenly if I feel better?

A: Official documents warn that therapy should not be stopped suddenly, particularly in the patient population with coronary artery disease. Stopping abruptly has been associated with severe risks. When discontinuation is necessary, it must involve a process of gradual dose reduction over a period of about one to two weeks.

Q: Does Nebivolol-Actavis interact with common over-the-counter pain relievers?

A: Official regulatory information indicates that this medicine may interact with drugs known as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a category that includes many common over-the-counter pain relievers. Co-administration may lead to a reduction in the blood pressure lowering effect of Nebivolol-Actavis.

Q: What should I do if my blood pressure still seems high while taking Nebivolol-Actavis?

A: When insufficient effect is observed, the official prescribing information describes that dose adjustments are permitted by the healthcare provider, typically at intervals of approximately two weeks. Consistent monitoring is key to determining if the medicine is achieving its documented therapeutic goal.

Q: Can I take Nebivolol-Actavis if I have diabetes?

A: The use of this medicine is subject to caution for patients with diabetes. Regulatory warnings state that Nebivolol-Actavis may mask certain symptoms of hypoglycemia (low blood sugar), such as a rapid heart rate. The need for blood sugar monitoring is noted for individuals managing this condition while taking this medicine.

Q: Is there any research showing Nebivolol-Actavis is beneficial for heart failure?

A: Yes. Regulatory documentation describes that Nebivolol has been studied and indicated for use in stable mild and moderate chronic heart failure. The evidence is centered on its use as an add-on to standard therapy in a specific population of elderly patients aged 70 years and over.

Q: Can Nebivolol-Actavis cause weight gain?

A: Official adverse reaction listings do not include weight gain as a common or uncommon side effect. However, official information does list unusual weight gain as a potential symptom of worsening heart failure, which is considered a serious but uncommon side effect.

Q: Are there any common long-term side effects of Nebivolol-Actavis that I should know about?

A: Clinical trials document common side effects that were observed over the study periods. The EMA Summary of Product Characteristics states that the long-term effects of Nebivolol are not fully established and there is limited information for use extending many years beyond the initial clinical trials.

Q: What is the difference between Nebivolol-Actavis and plain nebivolol?

A: Nebivolol is the pharmaceutical ingredient that provides the medical effect. Actavis is the name of the company responsible for producing and supplying this specific version of the medicine. The full name distinguishes it from other generic or brand-name products containing the same active ingredient.

Q: Is Nebivolol-Actavis known to affect sexual performance?

A: Official regulatory documents list impotence as an uncommon side effect. This means it has been reported to occur in 0.1% to 1% of patients during clinical study periods.

Q: Does alcohol affect how Nebivolol-Actavis works?

A: Yes, official documentation describes that consuming alcohol may have additive effects with Nebivolol-Actavis in lowering blood pressure. This could potentially increase the risk of experiencing symptoms such as dizziness, lightheadedness, or fainting.

Q: Is it true that Nebivolol-Actavis is different from older beta-blockers because of nitric oxide?

A: Yes. Regulatory information classifies Nebivolol as a third-generation beta-blocker. This classification is due to its dual mechanism, which includes its ability to block heart receptors and also promote blood vessel dilation through a process mediated by Nitric Oxide (NO).

Q: Can Nebivolol-Actavis cause dizziness or fatigue during the first few weeks?

A: Dizziness and fatigue are both listed as Common side effects of this medicine, meaning they affect between 1% and 10% of patients. Many common side effects, including dizziness and fatigue, have been reported in clinical studies.

Q: How long does the effect of one dose of Nebivolol-Actavis last?

A: Official regulatory documentation describes that the medicine's single, daily dose has been shown to sustain its efficacy over 24 hours. For this reason, a more frequent dosing regimen is not typically beneficial.

Q: Is Nebivolol-Actavis safe for elderly patients?

A: Nebivolol-Actavis is an allowed medicine for adults, including those who are elderly. It is specifically indicated for the treatment of heart failure in adults aged 70 years and over. While dosage adjustment is not typically needed for hypertension in the elderly, close attention is advised for patients over 75 years.

Q: What is the main purpose of the 'Actavis' part of the name?

A: The 'Actavis' component of the name serves to identify the manufacturer or the marketing authorization holder. This party is responsible for the production and distribution of this specific product formulation.

Q: Why is Nebivolol-Actavis sometimes prescribed for people with high blood pressure who also have specific heart issues?

A: Regulatory documents indicate that Nebivolol is used for two main purposes: the management of essential hypertension and the treatment of stable mild and moderate chronic heart failure in elderly patients. This dual indication is described in official documentation.

Q: Can women who are planning to become pregnant use Nebivolol-Actavis?

A: Official warnings state that use during the second and third trimesters of pregnancy is associated with a risk of fetal toxicity, and prompt discontinuation is advised if pregnancy is detected. Due to these risks, any use while planning pregnancy necessitates consulting a healthcare provider.

Q: Does Nebivolol-Actavis affect sleep or cause insomnia?

A: Yes. Official adverse reactions list both nightmares and difficulty sleeping or insomnia as uncommon side effects. These effects are reported in 0.1% to 1% of patients during clinical studies.

Q: Is it normal to feel cold hands and feet when starting Nebivolol-Actavis?

A: While specific clinical trial data does not list cold hands or feet as a common or uncommon side effect of Nebivolol, this effect is frequently associated with the broader beta-blocker class of medicines due to their effects on blood vessels. This is noted as a potential effect associated with the class of medicines.

Q: What kind of monitoring is typically needed when taking Nebivolol-Actavis?

A: Regulatory documents describe that consistent monitoring of blood pressure and heart rate is fundamental to treatment. Additionally, when initiating heart failure therapy or increasing the dose, close medical supervision is required for at least two hours after administration.

Q: Is Nebivolol-Actavis a medication that needs to be taken for life?

A: Nebivolol-Actavis is indicated for essential hypertension and chronic heart failure. These are conditions that generally require long-term, consistent management. The regulatory requirement for gradual discontinuation also indicates the expectation of continuous use for the duration determined by a healthcare provider.

Q: Does Nebivolol-Actavis have an effect on energy levels or mood?

A: Yes. Official documents list fatigue and tiredness as common side effects. Changes in mood are also noted, as depression and nightmares are listed as uncommon adverse effects.

Q: Is Nebivolol-Actavis used for conditions other than high blood pressure in some countries?

A: Yes. In the European Union (EU), Nebivolol is officially indicated for the treatment of stable mild and moderate chronic heart failure in elderly patients, in addition to its use for essential hypertension.

Q: Can I crush or split Nebivolol-Actavis tablets?

A: The heart failure protocol specifically mentions that a starting dose is often achieved by dividing a scored tablet, which indicates that certain scored tablets are designed to be split. There are no general instructions to crush or split tablets for other uses.

Q: What if I have low blood pressure already—is Nebivolol-Actavis still safe?

A: Official documentation lists conditions associated with dangerously low blood pressure, such as cardiogenic shock and decompensated cardiac failure, as absolute contraindications. Hypotension (low blood pressure) is also an uncommon side effect, suggesting caution is required when baseline blood pressure is low.

Advertisements

How should Nebivolol-Actavis be stored and disposed of?

Storage and Disposal Requirements

Nebivolol tablets must be stored at Controlled Room Temperature, officially defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C.

Required Conditions

  • Temperature: Store within the defined Controlled Room Temperature range; do not expose to excessive heat.
  • Moisture and Freezing: The product must be protected from moisture and should not be frozen to maintain stability.
  • Child Safety: Keep the tablets out of the sight and reach of children.

Disposal Guidelines

Unused or expired Nebivolol must be discarded according to official procedures. Disposal is recommended via an authorized drug take-back program. If this is not possible, the medicine may be disposed of in the household trash after being mixed with an unappealing substance, as the tablets are not on the FDA's flush list and must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nebivolol-Actavis found in:

A-Z Index: